Founded in 2020, iTolerance is regenerative medicine company developing a potential cure for Type 1 Diabetes that eliminates the need for chronic immunosuppression of patients.
The company’s lead program, ITOL-101, is an adjunct therapy with pancreatic islet cell implant currently in development for the treatment of or as a potential breakthrough cure for Type 1 Diabetes. As an adjunct therapy with pancreatic islet cells, the company says that ITOL-101 creates a durable, localized immune tolerance that has the potential to protect implanted islet cells from rejection by the body’s own immune system. This localized immune acceptance potentially eliminates the need for sustained immunosuppressants and allows for localized remodeling and functional engraftment. iTolerance reports that ITOL-101 has demonstrated compelling efficacy in non-human primate studies. The company plans to advance ITOL-101 towards an IND and first-in-man study.
In addition to ITOL-101, iTolerance is advancing its regenerative cell therapy platform to fuel a ‘robust’ pipeline addressing other high-value indications.